FDx Advisors Inc. Sells 620 Shares of Kenvue Inc. (NYSE:KVUE)

FDx Advisors Inc. lowered its stake in shares of Kenvue Inc. (NYSE:KVUE) by 4.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,721 shares of the company’s stock after selling 620 shares during the period. FDx Advisors Inc.’s holdings in Kenvue were worth $293,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of KVUE. AMF Tjanstepension AB raised its position in shares of Kenvue by 187.3% during the third quarter. AMF Tjanstepension AB now owns 120,477 shares of the company’s stock valued at $2,787,000 after buying an additional 78,540 shares during the last quarter. Sequoia Financial Advisors LLC grew its holdings in shares of Kenvue by 6.2% in the third quarter. Sequoia Financial Advisors LLC now owns 24,690 shares of the company’s stock valued at $571,000 after purchasing an additional 1,449 shares in the last quarter. Signaturefd LLC grew its holdings in shares of Kenvue by 394.0% in the third quarter. Signaturefd LLC now owns 4,061 shares of the company’s stock valued at $94,000 after purchasing an additional 3,239 shares in the last quarter. Commerzbank Aktiengesellschaft FI purchased a new position in shares of Kenvue in the third quarter valued at $292,000. Finally, International Assets Investment Management LLC grew its holdings in shares of Kenvue by 1,529.5% in the third quarter. International Assets Investment Management LLC now owns 106,341 shares of the company’s stock valued at $2,460,000 after purchasing an additional 99,815 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Up 0.5 %

Shares of KVUE opened at $22.38 on Friday. The firm has a market capitalization of $42.90 billion, a P/E ratio of 42.22, a P/E/G ratio of 2.61 and a beta of 1.45. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The firm has a fifty day moving average price of $21.29 and a 200-day moving average price of $22.14.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Equities research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be issued a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 3.66%. Kenvue’s payout ratio is currently 154.72%.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on KVUE shares. Royal Bank of Canada reissued a “sector perform” rating and issued a $24.00 target price on shares of Kenvue in a report on Monday, February 3rd. Piper Sandler raised shares of Kenvue from a “neutral” rating to an “overweight” rating and raised their target price for the company from $21.00 to $26.00 in a report on Monday, January 6th. UBS Group cut their target price on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a report on Friday, February 7th. Barclays cut their target price on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a report on Friday, January 17th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $25.00 to $24.00 in a research note on Thursday, December 12th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, Kenvue currently has an average rating of “Hold” and a consensus price target of $23.00.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.